IDH2 and central nervous system cancer: Study of orally administered AG-221 in subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell lymphoma, with an IDH2 mutation subjects with advanced solid tumors, including glioma, and with angioimmunoblastic T-cell